

Lokorejyonal Rekürrens, Metastazlarda ve Primer Tiroid Kanserlerinde Lokal Tedaviler

- Prof. Dr. Bekir ÇAKIR
- Prof. Dr. Didem ÖZDEMİR
- Uz. Dr. Gökhan YÜCE

Özet

Tiroid kanserlerinde prognoz çoğunlukla iyi olmakla birlikte bazı hastalarda takipte lokal rekürrens ve boyunda lenf nodu metastazı görülebilir. Bu hastalarda ilk seçenek cerrahi tedavidir. Diğer seçenekler radyoaktif iyot tedavisi, radyoterapi, kemoterapi ve immunoterapi olmakla birlikte etkinlikleri sınırlıdır. Son yıllarda cerrahi riski yüksek veya tekrarlayan cerrahi girişimi kabul etmeyen hastalarda lokorejyonel rekürrens veya metastaz varlığında görüntüleme eşliğinde lokal tedaviler uygulanmaya başlanmıştır. Bu tedaviler perkütan etanol enjeksiyonu ve termal ablasyondur (radyofrekans ablasyon, perkütan lazer ablasyon ve mikrodalga ablasyon). Önceleri metastatik lezyonlarda uygulanan bu yöntemler daha sonra özellikle 1 cm altında lokal veya uzak metastazı olmayan primer iyi diferansiye tiroid kanserlerinde de kullanılmıştır. Çalışmalarda lokal tedaviler ile tümör boyutlarında belirgin azalma, serum tiroglobulinde belirgin düşme ve değişen oranlarda tümörde tamamen kaybolma bildirilmiştir. Bununla birlikte bu çalışmaların çoğunlukla takip süreleri kısadır ve uzun dönem verileri olan çalışma sayısı oldukça azdır. Bu nedenle uzun dönem sonuçları, morbidite ve mortalite üzerine etkileri net değildir. Ayrıca, cerrahiye oranla yan etkileri daha az olsa da ağrı, kanama, geçici veya kalıcı ses değişikliği, hematoma, deri yanıkları gibi komplikasyonlar görülebilir. Günümüze kadar olan verilerle primer tiroid kanserlerinde bu yöntemlerin önerilmesi söz konusu değildir. Rekürrens veya lokal metastaz varlığında ise cerrahi kabul etmeyen veya cerrahi uygulanamayan hastalarda alternatif olarak uygulanabilir.

Teşekkür: Radyofrekans ablasyon ve mikrodalga ablasyon cihaz görüntülerinin (şekil 2 ve 15) kullanımını için izin veren Medel Tıp Medikal Limited Şirketi'ne teşekkür ederiz

Çıkar çatışması: Yazarlar, bu kitap bölümünün hazırlanması, yazılması ve basılması sırasında herhangi bir firma veya grup ile herhangi bir ticari çıkar çatışması içinde bulunmamışlardır.

Kaynaklar

1. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. *Surgery* 1988;104:947-53.
2. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. *Surgery* 1993;114:1050-7; discussion 1057-8.
3. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines-Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016;26(1):1-133.
4. Pironi D, Pontone S, Vendettuoli M, Podzemny V, Mascagni D, Arcieri S, et al. Prevention of complications during reoperative thyroid surgery. *Clin Ter* 2014;165(4):e285-90
5. Shaha AR. Revision thyroid surgery - technical considerations. *Otolaryngol Clin North Am*. 2008;41(6):1169-83
6. Kim JH, Baek JH, Lim HK, et al. Guideline Committee for the Korean Society of Thyroid Radiology (KSThR) and Korean Society of Radiology. 2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology. *Korean J Radiol* 2018;19(4):632-55.
7. Jeong SY, Baek JH, Choi YJ, et al. Ethanol and thermal ablation for malignant thyroid tumours. *Int J Hyperthermia* 2017;33(8):938-45.
8. Ji L, Wu Q, Gu J, et al. Ultrasound-guided percutaneous laser ablation for papillary thyroid microcarcinoma: a retrospective analysis of 37 patients. *Cancer Imaging*. 2019;19(1):16.
9. Yue W, Wang S, Yu S, Wang B. Ultrasound-guided percutaneous microwave ablation of solitary T1N0M0 papillary thyroid microcarcinoma: initial experience. *Int J Hyperthermia*. 2014;30(2):150-7.
10. Zhang M, Luo Y, Zhang Y, et al. Efficacy and safety of ultrasound-guided radiofrequency ablation for treating low risk papillary thyroid microcarcinoma: a prospective study. *Thyroid* 2016;26:1581-7.
11. Kim JH, Baek JH, Sung JY, Min HS et al. Radiofrequency ablation of low-risk small papillary thyroid carcinoma: preliminary results for patients ineligible for surgery. *Int J Hyperthermia* 2017;33(2):212-9.
12. Zhang L, Zhou W, Zhan W, et al. Percutaneous laser ablation of unifocal papillary thyroid microcarcinoma: utility of conventional ultrasound and contrast-enhanced ultrasound in assessing local therapeutic response. *World J Surg* 2018;42:2476-84.
13. Li J, Liu Y, Liu J, et al. Ultrasound-guided percutaneous microwave ablation versus surgery for papillary thyroid microcarcinoma. *Int J Hyperthermia* 2018;34(5):653-9.
14. Çakır B. Noduler Tiroid Hastalıklarında Ultrason Eşliğinde Tedavi Uygulamaları: Perkutan Etanol Enjeksiyonu, Perkutan Lazer Termal Ablasyon, Radyofrekans Ablasyon, Yüksek Yoğunlukta Odaklanmış Ultrasonik Ses Dalgası Tedavisi; Tedavi Endikasyonları, Farklı Teknik Uygulamalar, Yan Etki ve Komplikasyonlar, Kısa ve Uzun Donem Tedavi Sonuçları. *Türkiye Klinikleri J Endocrin-Special Topics* 2008;1(3):36-53
15. Baek JH, Kim YS, Sung JY, et al. Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound guided radiofrequency ablation. *AJR Am J Roentgenol* 2011;197(2):W331-6.
16. Dupuy DE, Monchik JM, Decrea C, et al. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. *Surgery* 2001;130:971-7.
17. Lewis BD, Hay ID, Charboneau JW, et al. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. *Am J Roentgenol* 2002;178:699-704.
18. Monchik JM, Donatini G, Iannucilli J, et al. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. *Ann Surg* 2006;244:296-304.
19. Heilo A, Sigstad E, Fagerlid KH, et al. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2011;96:2750-5.
20. Hay ID, Lee RA, Davidge-Pitts C, et al. Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. *Surgery* 2013;154:1448-54. discussion 54-5.
21. Kim BM, Kim MJ, Kim E-K, et al. Controlling recurrent papillary thyroid carcinoma in the neck by ultrasonography-guided percutaneous ethanol injection. *Eur Radiol* 2008;18:835-42.
22. Vannucchi G, Covelli D, Perrino M, et al. Ultrasound-guided percutaneous ethanol injection in papillary thyroid cancer metastatic lymph-nodes. *Endocrine* 2014;47(2):648-51.
23. Kim SY, Kim SM, Chang H, et al. Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid can-

- cer. *Eur Arch Otorhinolaryngol* 2017;274(9):3497-501.
24. Fontenot TE, Deniwar A, Bhatia P, et al. Percutaneous Ethanol Injection vs Reoperation for Locally Recurrent Papillary Thyroid Cancer: A Systematic Review and Pooled Analysis. *JAMA Otolaryngol Head Neck Surg* 2015;141:512-8.
 25. Angelini F, Nacamulli D, De Vido D, et al. Treatment of hot thyroid nodule with percutaneous ethanol injection: indications, complications, and prognostic factors. *Radiol Med*. 1996;91(6):774-80.
 26. Rodriguez-Lomba E, Molina-Lopez I, Parra-Blanco V, et al. Cutaneous implantation of papillary thyroid carcinoma secondary to percutaneous ethanol injection into nodal metastasis. *J Eur Acad Dermatol Venereol*. 2018;32(1):e11-e13.
 27. Park HS, Baek JH, Park AW, et al. Thyroid radiofrequency ablation: updates on innovative devices and techniques. *Korean J Radiol* 2017;18:615-23.
 28. Lee SJ, Jung SL, Kim BS, et al. Radiofrequency ablation to treat loco-regional recurrence of well-differentiated thyroid carcinoma. *Korean J Radiol* 2014;15:817-26.
 29. Wang L, Ge M, Xu D, et al. Ultrasonography-guided percutaneous radiofrequency ablation for cervical lymph node metastasis from thyroid carcinoma. *J Cancer Res Ther* 2014;10:C144-9.
 30. Lim HK, Baek JH, Lee JH, et al. Efficacy and safety of radiofrequency ablation for treating loco-regional recurrence from papillary thyroid cancer. *Eur Radiol* 2015;25:163-70.
 31. Kim JH, Yoo WS, Park YJ, et al. Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm. *Radiology* 2015;276:909-18.
 32. Guang Y, Luo Y, Zhang Y, et al. Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma. *J Cancer Res Clin Oncol*. 2017;143(8):1555-62.
 33. Chung SM, Baek JH, Choi YJ, et al. Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer. *Eur Radiol*. 2019 Feb 25. doi: 10.1007/s00330-019-06063-5. [Epub ahead of print]
 34. Suh CH, Baek JH, Choi YJ, et al. Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer: a systematic review and meta-analysis. *Thyroid* 2016;26:420-8.
 35. Choi Y, Jung SL, Bae JS, et al. Comparison of efficacy and complications between radiofrequency ablation and repeat surgery in the treatment of locally recurrent thyroid cancers: a single-center propensity score matching study. *Int J Hyperthermia*. 2019;36(1):359-67.
 36. Ha SM, Sung JY, Baek JH, et al. Radiofrequency ablation of small follicular neoplasms: initial clinical outcomes. *Int J Hyperthermia* 2017;33(8):931-7.
 37. Jeong SY, Baek JH, Choi YJ, et al. Radiofrequency ablation of primary thyroid carcinoma: efficacy according to the types of thyroid carcinoma. *Int J Hyperthermia* 2018;34(5):611-6.
 38. Kim C, Lee JH, Choi YJ, et al. Complications encountered in ultrasonography-guided radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers. *Eur Radiol* 2017;27:3128-37.
 39. Park KW, Shin JH, Han BK, et al. Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. *Ann Surg Oncol* 2011;18:2564-8.
 40. Baek JH, Lee JH, Sung JY, et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study. *Radiology* 2012;262(1):335-42.
 41. Guo H, Liu XL, Wang YL, et al. Protection of skin with subcutaneous administration of 5% dextrose in water during superficial radiofrequency ablation in a rabbit model. *Int J Hyperthermia* 2014;30:258-65.
 42. Oddo S, Spina B, Vellone VG, et al. A case of thyroid cancer on the track of the radiofrequency electrode 30 months after percutaneous ablation. *J Endocrinol Invest*. 2017;40:101-2.
 43. Chung SR, Suh CH, Baek JH, et al. Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: a systematic review and meta-analysis. *Int J Hyperthermia* 2017;33:920-30.
 44. Guenette BA, Monchik JM, Dupuy DE, et al. Image-guided Ablation of Postsurgical Locoregional Recurrence of Biopsy-proven Well-differentiated Thyroid Carcinoma. *J Vasc Interv Radiol* 2013;24:672-9.
 45. Cakir B, Ugras NS, Gul K, Ersoy R, et al. Initial report of the results of percutaneous laser ablation of benign cold thyroid nodules: evaluation of histopathological changes after 2 years. *Endocr Pathol*. 2009;20(3):170-6.
 46. Mauri G, Nicosia L, Della Vigna P, et al. Percutaneous laser ablation for benign and malignant thyroid diseases. *Ultrasonography* 2019;38(1):25-36.
 47. Cakir B, Topaloglu O, Gul K, et al. Effects of percutaneous laser ablation treatment in benign solitary thyroid nodules on nodule volume, thyroglobulin and anti-thyroglobulin levels, and cytopathology of nodule in 1 yr follow-up. *J Endocrinol Invest*. 2006;29(10):876-84.
 48. Cakir B, Topaloglu O, Gul K, et al. Ultrasound-guided percutaneous laser ablation treatment in inoperable aggressive course anaplastic thyroid carcinoma: the introduction of a novel alternative palliative therapy- -second experience in the literature. *J Endocrinol Invest* 2007;30:624-5.
 49. Pacella CM, Bizzarri G, Spiezia S, et al. Thyroid tissue: US-guided percutaneous laser thermal ablation. *Radiology* 2004;232:272-80.
 50. Papini E, Bizzarri G, Bianchini A, et al. Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer. *J Clin Endocrinol Metab* 2013;98:E92-7.
 51. Mauri G, Cova L, Ierace T, et al. Treatment of metastatic lymph nodes in the neck from papillary thyroid carcinoma with percutaneous laser ablation. *Cardiovasc Intervent Radiol* 2016;39(7):1023-30.
 52. Zhang L, Zhou W, Zhan W. Role of ultrasound in the assessment of

- percutaneous laser ablation of cervical metastatic lymph nodes from thyroid carcinoma. *Acta Radiol* 2018;59:434-40.
53. Mauri G, Cova L, Tondolo T, et al. Percutaneous laser ablation of metastatic lymph nodes in the neck from papillary thyroid carcinoma: preliminary results. *J Clin Endocrinol Metab* 2013;98:E1203-7.
54. Zhou W, Zhang L, Zhan W, et al. Percutaneous laser ablation for treatment of locally recurrent papillary thyroid carcinoma <15 mm. *Clin Radiol* 2016;71:1233-9.
55. Persichetti A, Bizzarri G, Guglielmi R, et al. Ultrasound-guided laser ablation for local control of neck recurrences of medullary thyroid cancer. A feasibility study. *Int J Hyperthermia* 2018;35(1):480-92.
56. Papini E, Guglielmi R, Gharib H, et al. Ultrasound-guided laser ablation of incidental papillary thyroid microcarcinoma: a potential therapeutic approach in patients at surgical risk. *Thyroid* 2011;21(8):917-20.
57. Valcavi R, Piana S, Bortolan GS, et al. Ultrasound-guided percutaneous laser ablation of papillary thyroid microcarcinoma: a feasibility study on three cases with pathological and immunohistochemical evaluation. *Thyroid* 2013;23(12):1578-82.
58. Zhou W, Jiang S, Zhan W, et al. Ultrasound-guided percutaneous laser ablation of unifocal T1N0M0 papillary thyroid microcarcinoma: preliminary results. *Eur Radiol*. 2017;27(7):2934-40.
59. Cakir, B., Gul K, Ersoy R, Topaloglu O, et al. Subcapsular hematoma complication during percutaneous laser ablation to a hypoactive benign solitary thyroid nodule. *Thyroid* 2008;18(8):917-918
60. Yue W, Chen L, Wang S, Yu S. Locoregional control of recurrent papillary thyroid carcinoma by ultrasound-guided percutaneous microwave ablation: a prospective study. *Int J Hyperthermia* 2015;31:403-8.
61. Teng D, Ding L, Wang Y, et al. Safety and efficiency of ultrasound-guided low power microwave ablation in the treatment of cervical metastatic lymph node from papillary thyroid carcinoma: a mean of 32 months follow-up study. *Endocrine* 2018;62(3):648-54.
62. Li J, Liu Y, Liu J, Yang P, Hu X, Qian L. A comparative study of short-term efficacy and safety for thyroid micropapillary carcinoma patients after microwave ablation or surgery. *Int J Hyperthermia*. 2019;36(1):640-646.
63. Teng D, Sui G, Liu C, et al. Long-term efficacy of ultrasound-guided low power microwave ablation for the treatment of primary papillary thyroid microcarcinoma: a 3-year follow-up study. *J Cancer Res Clin Oncol* 2018;144(4):771-9